First line Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Authored by Fred Saad, published on 2026-06-19 18:20:05.0

The algorithm is broadly aligned with contemporary mCRPC practice in emphasizing prior exposure and mechanism switching (ARPI, taxanes, radiopharmaceuticals, and PARP inhibition for HRR-altered disease). It appropriately includes PSMA-targeted radioligand therapy after prior ARPI and docetaxel, and reserves radium-223 for symptomatic bone-predominant disease without visceral metastases. The main limitation is that some PARP+ARPI combinations are primarily supported/approved in earlier (mCSPC) settings or have evolving/region-specific indications, so “first-line mCRPC” labeling may overgeneralize. Overall, it reflects guideline-consistent sequencing concepts but needs clearer line-of-therapy and eligibility details (e.g., prior ARPI in mCSPC vs mCRPC; PSMA PET criteria; hematologic/visceral disease constraints).

  1. First line mCRPC
    Preference for agents not previously received and a change in mechanism of action. Consider clinical trials.
    • Post ARPI
      • Docetaxel
      • If symptomatic + no visceral metastases: Radium-223*
    • Post ARPI and docetaxel
      • If PSMA-expressing lesions: 177Lu-PSMA-617 (up to six cycles)
      • Cabazitaxel
        • If symptomatic + no visceral metastases: Radium-223*
    • Post docetaxel
      • Abiraterone, or Enzalutamide, or Cabazitaxel
        After docetaxel, ARPIs (abiraterone or enzalutamide) and cabazitaxel are guideline-supported options; choice depends on prior exposures and patient factors. Evidence cautions against routine ARPI-to-ARPI sequencing when one ARPI has already been used.
      • If symptomatic + no visceral metastases: Radium-223*
    • HRR mutation
      • No prior ARPI
        • Niraparib + Abi, or Olaparib + Abi, or Talazoparib + Enza
      • Prior ARPI
        • Olaparib
    • Post ADT alone
      • Abiraterone, or Enzalutamide, or Docetaxel
tosprivacy